Eva Moskowitz grew up in the neighborhood of Morningside Heights, Manhattan. She graduated from Stuyvesant High School where “she believed half of the teachers there were incompetent” according to Steven Brill. Early on in her career after receiving a Ph.D. from Johns Hopkins University she taught women’s history at the University of Virginia as a visiting professor, also at Vanderbilt University as an assistant professor, and at City University of New York also as an assistant professor of history.
Eva Moskowitz, the founder of the Success Academy Education Institute(Charter School) is looking to change public policies and public school design in order to assure that more kids are getting educational excellence. Eva Moskowitz is showing the nation what is possible by doing everything differently from the aesthetics of schooling, to the way math is being taught, to the way financial operations are run.
Eva Moskowitz’ school after achieving great results decided to allow other educators the ability to access their blueprints which will empower them to hone their craft and be able to hone their ability to be a great teacher. This is amazing because it shows that Eva Moskowitz cares about not just the education of her own students but is also attempting to spread the resources and allow others to benefit and grow from her educational methods. She believes more high quality options need to be there for students because there are huge amounts of students not getting the quality education they need and there are somewhere near 50,000 students stuck on charter school waiting lists and they won’t all get in. Eva Moskowitz’ Charter School System is reimagining the way K-12 public education is being taught and is achieving excellent results for her students.
When cancer treatment is mentioned, most people think of it like a nightmare. However, innovative scientists like Clay Siegall have played a significant role towards changing the situation. Siegall became aware of cancer through his father who struggled with it for about five years. During the time, oncologists faced great challenges associated with limited tools for cancer treatment, and this made it hard for patients to survive.
From the experience, Clay got an urge to carry out research and improve facilities in future in order to save the lives of desperate cancer patients. His goal has been to introduce innovative and effective cancer treatment therapies and to alleviate their suffering through targeted cancer drugs. His achievements in the industry have increased through the establishment of partnerships and collaborating with other professionals, innovators, scientists, and leaders.
Clay Siegall dreams of making a difference through improved cancer treatment started when he enrolled to study Genetics and Zoology. He holds a Doctorate in Genetics from the University of George Washington and a Bachelor of Science degree in Zoology from Maryland. His career started at a pharmaceutical research institute under Bristol-Myers Squib before he joined the National Cancer Institute and the National Institutes of Health.
He has served as one of the Board of Directors at Ultragenyx Pharmaceutical, Alder Biopharmaceutical, and Washington Roundtable. Clay’s dream became a reality when he founded Seattle Genetics in 1998 and chose to put into practice the knowledge and skills he had gained from the previous roles. Currently, he is the Chief Executive Officer of the celebrated Seattle Genetics. The company focuses on research and development of cancer therapies.
Under clay’s leadership, Settle Genetics has laid the foundation for enhanced cancer treatment through scientific innovation, extensive research, and drug advancement. For instance, Seattle Genetics in collaboration with Takeda Pharmaceuticals Company developed effective antibody-drug conjugates. The drug attained the FDA approval in 2011, and it is now a global brand accessible in more than 65 countries worldwide. As more firms involved in cancer research and treatment discover the effectiveness of Seattle’s ADC technology, many of them are seeking to enter into agreements with Clay Siegall and Seattle Genetics to further development.